China’s delay in approval of GM cotton could cost Australian oilseed farmers hundreds of millions of dollars

r w h fmax

A lack of regulatory approval from China for cotton seed produced from the genetically modified (GM) Bollgard 3 suite of cotton varieties could cost the Australian oilseed exporting sector hundreds of millions of dollars if not resolved.

It is expected Australia will produce around one million tonnes of cotton seed this year, with around 90-95 per cent of plantings of Bollgard 3 varieties.

With subdued domestic demand for cotton seed, the industry was targeting the export market, in particular China as a home for the product.

The confusion over China’s position on Bollgard 3 has caught the industry on the hop.

In its promotion of the Bollgard 3 technology, patent owners Monsanto stated the trait had received seed import approval in China.

However, all exporters are required to do their own due diligence on regulatory requirements for individual markets before committing to sales.

The Australian Government is now in discussions with China over the issue.

The problem is damaging for the owners of the Bollgard 3 patent, Monsanto, who had been delighted with how Bollgard 3 had performed agronomically in its first season.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Chinese approval delay a blow for cottonseed producers

For more background on the Genetic Literacy Project, read GLP on Wikipedia

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Picture1
The FDA couldn’t find a vaccine safety crisis, so it buried its own research
Screenshot-2026-04-22-at-12.21.32-PM
Viewpoint: Why the retracted Monsanto glyphosate study doesn’t change the science—the world’s most popular herbicide is safe 
ChatGPT-Image-May-7-2026-12_32_36-PM
Viewpoint: The state of U.S. vaccine policy? Dismal nationally, but some states are stepping up.
Screenshot-2026-04-22-at-10.46.29-AM
Viewpoint: How to counter science disinformation? Science journalist offers 12 practical tips
Screenshot-2026-04-13-at-1.39.26-PM
Viewpoint: ‘Safer for children?’ Stonyfield yogurt under fire for deceptive organic marketing
ChatGPT-Image-May-7-2026-12_16_37-PM-2
Viewpoint: Are cancer rates ‘skyrocketing’ as RFK, Jr. and MAHA claim? The evidence says mostly the opposite
the magic of mRNA
Viewpoint: Anti-vax fake ‘turbo cancer’ claims threaten cancer treatment breakthroughs
placebo
Viewpoint — Alternative medicine and the placebo effect: Selling a reassuring illusion of health
Defense_Secretary_Ash_Carter_tours_the_Microsoft_Cybercrime_Center_in_Seattle_March_3_2016
How criminals are using AI to target social media users and steal their money and confidential data
ChatGPT-Image-May-18-2026-01_45_05-PM-2
Newest hantavirus conspiracy: Online disinformation turns outbreak into latest ivermectin grift
artificial intelligence brain think illustration md
Viewpoint — Digital gods and human extinction: Will we be the first species ever to design our own descendants?
_20250221_nib_rfk_trump
Viewpoint: 'Crisis of public trust': Autism support community shocked RFK continues to peddle false claims about the danger of vaccines
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.